These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

922 related articles for article (PubMed ID: 30841523)

  • 1. HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer.
    Rinnerthaler G; Gampenrieder SP; Greil R
    Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30841523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
    Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
    Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
    Corrigan PA; Cicci TA; Auten JJ; Lowe DK
    Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane.
    Li C; Wang B; Chen SC; Wada R; Lu D; Wang X; Polhamus D; French J; Vadhavkar S; Strasak A; Smitt M; Joshi A; Samant M; Quartino A; Jin J; Girish S
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1079-1090. PubMed ID: 29022084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel HER2-targeted therapies for HER2-positive metastatic breast cancer.
    Kunte S; Abraham J; Montero AJ
    Cancer; 2020 Oct; 126(19):4278-4288. PubMed ID: 32721042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer.
    Krop I; Winer EP
    Clin Cancer Res; 2014 Jan; 20(1):15-20. PubMed ID: 24135146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer.
    Barok M; Le Joncour V; Martins A; Isola J; Salmikangas M; Laakkonen P; Joensuu H
    Cancer Lett; 2020 Mar; 473():156-163. PubMed ID: 31904483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
    Ogitani Y; Hagihara K; Oitate M; Naito H; Agatsuma T
    Cancer Sci; 2016 Jul; 107(7):1039-46. PubMed ID: 27166974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer.
    Van den Mooter T; Teuwen LA; Rutten A; Dirix L
    Expert Opin Biol Ther; 2015 May; 15(5):749-60. PubMed ID: 25865453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer.
    Boyraz B; Sendur MA; Aksoy S; Babacan T; Roach EC; Kizilarslanoglu MC; Petekkaya I; Altundag K
    Curr Med Res Opin; 2013 Apr; 29(4):405-14. PubMed ID: 23402224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
    Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S
    Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal treatment of early stage HER2-positive breast cancer.
    Pernas S; Barroso-Sousa R; Tolaney SM
    Cancer; 2018 Dec; 124(23):4455-4466. PubMed ID: 30291791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab emtansine in HER2-positive metastatic breast cancer: what is the best sequence?
    Ricci F; Le Tourneau C
    Chin Clin Oncol; 2018 Feb; 7(1):3. PubMed ID: 29156892
    [No Abstract]   [Full Text] [Related]  

  • 14. Trastuzumab emtansine: determining its role in management of HER2+ breast cancer.
    Doroshow DB; LoRusso PM
    Future Oncol; 2018 Mar; 14(7):589-602. PubMed ID: 29214842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer.
    Haddley K
    Drugs Today (Barc); 2013 Nov; 49(11):701-15. PubMed ID: 24308017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer.
    Wang L; Wang Q; Gao M; Fu L; Li Y; Quan H; Lou L
    Cancer Sci; 2018 Oct; 109(10):3305-3315. PubMed ID: 30076657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature.
    Martínez MT; Pérez-Fidalgo JA; Martín-Martorell P; Cejalvo JM; Pons V; Bermejo B; Martín M; Albanell J; Lluch A
    Crit Rev Oncol Hematol; 2016 Jan; 97():96-106. PubMed ID: 26318092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
    Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
    J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
    Baron JM; Boster BL; Barnett CM
    J Oncol Pharm Pract; 2015 Apr; 21(2):132-42. PubMed ID: 24682654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and responses of brain metastases during treatment with trastuzumab emtansine (T-DM1) for HER2 positive advanced breast cancer: A single institution experience.
    Okines A; Irfan T; Khabra K; Smith I; O'Brien M; Parton M; Noble J; Stanway S; Somaiah N; Ring A; Johnston S; Turner N
    Breast J; 2018 May; 24(3):253-259. PubMed ID: 28833867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.